Name: Global pharma giants ramp up investments in China's biotech sector
Uploaded: 2026-03-23T12:06:04+08:00
Duration: 1 min 41 s
Description: Following China's Two Sessions, executives from world-leading pharmaceutical companies visited Beijing to explore new opportunities. For the first time, biomedicine has been designated as an emerging pillar industry, as China accelerates efforts to build

Language

RSS

Newsletters

Home

China

World

Politics

Business

Sci-Tech

Health

Opinions

Video

Live

Radio

World Asia-Pacific Middle East Europe Americas Africa

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.

I agree

Following China's Two Sessions, executives from world-leading pharmaceutical companies visited Beijing to explore new opportunities. For the first time, biomedicine has been designated as an emerging pillar industry, as China accelerates efforts to build a "Healthy China" by 2035.

Major investments, including Eli Lilly's $3 billion plan and AstraZeneca's about$14 billion commitment, underscore the strong appeal of the Chinese market for global drugmakers.

01:42

Open in CGTN APP for better experience

Search Trends